Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

231
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
231
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

239
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
239
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

343
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
343
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

174
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
174
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

215
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
215
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

99
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
99

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychiatric Risk in Chronic Spontaneous Urticaria: A Retrospective Cohort Study.

Acta dermato-venereologica·2026
Same author

Efficacy of digital therapeutic sinCephalea for personalised nutrition versus control for migraine prevention: A 12-week open-label randomised clinical trial.

Cephalalgia : an international journal of headache·2026
Same author

Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin).

Dermatology and therapy·2026
Same author

Long-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summary.

The Journal of dermatological treatment·2026
Same author

Atopic dermatitis Yardstick: A new era of topical and systemic treatments.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Repeated switching between biosimilar ABP 654 and reference ustekinumab in patients with moderate-to-severe plaque psoriasis: a randomized, double-blinded clinical trial to support interchangeability.

The British journal of dermatology·2026

Related Experiment Video

Updated: May 28, 2025

A Mouse Ear Model for Allergic Contact Dermatitis Evaluation
08:02

A Mouse Ear Model for Allergic Contact Dermatitis Evaluation

Published on: March 24, 2023

3.2K

What Does Long-Term Control in Atopic Dermatitis Look Like?

Shanthi Narla1, Zelma C Chiesa Fuxench2, Katrina Abuabara3

  • 1From the Department of Dermatology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

Dermatitis : Contact, Atopic, Occupational, Drug
|February 10, 2025
PubMed
Summary

Defining and measuring long-term control in atopic dermatitis (AD) is challenging due to its varied nature. Achieving disease modification through effective long-term control strategies is crucial for managing AD and its comorbidities.

More Related Videos

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

9.6K
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.1K

Related Experiment Videos

Last Updated: May 28, 2025

A Mouse Ear Model for Allergic Contact Dermatitis Evaluation
08:02

A Mouse Ear Model for Allergic Contact Dermatitis Evaluation

Published on: March 24, 2023

3.2K
Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

9.6K
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.1K

Area of Science:

  • Dermatology
  • Immunology

Background:

  • Atopic dermatitis (AD) is a complex skin condition with heterogeneous presentation.
  • Measuring long-term control and defining flares in AD lacks consensus due to individual patient experiences.

Purpose of the Study:

  • To critically examine the definition, measurement, and importance of long-term control in atopic dermatitis.
  • To explore clinical rationale, assessment approaches, mechanistic underpinnings, and evidence for long-term control with systemic AD treatments.

Main Methods:

  • Critical review of existing literature on atopic dermatitis long-term control.
  • Examination of current systemic treatments and their long-term efficacy.
  • Exploration of potential disease modification and remission strategies.

Main Results:

  • Limited consensus exists on defining AD flares and long-term control.
  • Disease modification, impacting the disease and its comorbidities, is key to long-term control.
  • Current research on long-term efficacy of systemic AD therapies is ongoing, requiring larger studies.

Conclusions:

  • Achieving deep or therapy-free remission in AD may be possible by addressing multiple facets of long-term control.
  • Further research with extended follow-up is necessary to validate reduced dosing strategies for patients in remission.
  • Future AD therapies may focus on modulating innate and adaptive immunity for disease modification.